Meeting News CoverageVideo

VIDEO: DCB yields superior 3-year outcomes vs. angioplasty

LAS VEGAS — In this video, Prakash Krishnan, MD, presents 3-year data from the IN.PACT SFA Randomized Trial that show improved outcomes with a drug-coated balloon compared with percutaneous transluminal angioplasty for treatment of symptomatic femoropopliteal lesions

During an interview at VIVA 16, Krishnan reported that treatment with the DCB (IN.PACT Admiral, Medtronic) yielded superior primary patency at 3 years compared with angioplasty (69.5% vs. 45.1%; P < .001). The data show “an absolute risk reduction of restenosis of 24.4%, which is highly statistically significant,” Krishnan, director of endovascular interventions at The Mount Sinai Hospital Cardiac Catheterization Laboratory and professor of medicine – cardiology and radiology, said.

The new 3-year data prove that “the IN.PACT [DCB] is durable, safe and may become the primary therapy for the treatment of femoropopliteal disease,” Krishnan said.

LAS VEGAS — In this video, Prakash Krishnan, MD, presents 3-year data from the IN.PACT SFA Randomized Trial that show improved outcomes with a drug-coated balloon compared with percutaneous transluminal angioplasty for treatment of symptomatic femoropopliteal lesions

During an interview at VIVA 16, Krishnan reported that treatment with the DCB (IN.PACT Admiral, Medtronic) yielded superior primary patency at 3 years compared with angioplasty (69.5% vs. 45.1%; P < .001). The data show “an absolute risk reduction of restenosis of 24.4%, which is highly statistically significant,” Krishnan, director of endovascular interventions at The Mount Sinai Hospital Cardiac Catheterization Laboratory and professor of medicine – cardiology and radiology, said.

The new 3-year data prove that “the IN.PACT [DCB] is durable, safe and may become the primary therapy for the treatment of femoropopliteal disease,” Krishnan said.

    See more from VIVA